Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A promising new drug for a tricky post-surgery complication. Amylyx Pharmaceuticals announced that avexitide, a once-daily injection, reduced dangerous low blood sugar episodes by 55% compared to placebo in a late-stage trial for post-bariatric hypoglycemia. With no approved treatments currently available, Amylyx plans to seek FDA approval by year-end and aims for a commercial launch in 2027.
A promising fix for a dangerous post-surgery complication
Amylyx Pharmaceuticals just delivered a significant win for bariatric surgery patients. Its experimental drug avexitide hit its primary endpoint in a late-stage trial, cutting dangerous low blood sugar episodes by 55% compared to placebo over 16 weeks — well above the 35–50% reduction analysts had projected as an encouraging outcome. The drug works by blocking GLP-1 receptors on insulin-producing pancreatic cells, reining in excess insulin secretion and stabilizing blood glucose levels.
Post-bariatric hypoglycemia affects roughly 8% of weight-loss surgery patients in the U.S. and can trigger serious consequences including cognitive impairment, loss of consciousness, and seizures. Right now, there are zero approved treatments — patients rely on dietary adjustments, blood sugar monitoring, and carbohydrate-blocking medications to manage the condition.
By the Numbers
Why it matters: With FDA submission planned for late 2026 and a potential commercial launch in 2027, avexitide could become the first approved therapy for a condition that has long left patients without a medical solution.
